# BMP1 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- BMP1 is a secreted metalloprotease (M12A family) essential for extracellular matrix (ECM) organization, primarily by cleaving the C-terminal propeptides of fibrillar collagens (types I, II, III, V, VII), a critical step for fibril assembly.
- Loss-of-function mutations in BMP1 lead to autosomal recessive osteogenesis imperfecta (OI types XII and XIII), characterized by skeletal fragility, bone deformities, and in severe cases, perinatal lethality, due to impaired collagen processing and ER stress.
- BMP1 also functions as a chordinase, cleaving the BMP antagonist chordin to release active BMP2/4, thereby regulating dorsoventral patterning in embryogenesis and contributing to fibrotic processes via a TGF-β positive feedback loop.
- Heterozygous gain-of-function mutations in BMP1, such as p.Pro707Leu, result in a high bone mass phenotype due to increased catalytic efficiency and excessive collagen crosslinking, demonstrating a distinct clinical outcome from loss-of-function variants.
- BMP1 is implicated in wound healing and cancer progression through its cleavage of laminin-5 and modulation of growth factor bioavailability (IGFBP3), and its activity is exploited by viral pathogens like HBV and HPV to promote fibrosis and invasion.
- Therapeutic strategies targeting BMP1 include small-molecule inhibitors (e.g., UK-383,367) for anti-fibrotic therapy and gene therapy approaches (e.g., AAV-BMP1 shRNA) for conditions like aortic aneurysm, while specific pharmacogenomic variants can influence treatment response.

---

## Executive Summary & Key Metadata

The **BMP1** gene encodes bone morphogenetic protein 1, a metalloprotease that operates as a key extracellular matrix (ECM) organizer and a critical regulator of morphogen signaling. Despite its historical classification alongside the TGF-β superfamily of growth factors, BMP1 is not a signaling ligand; rather, it is a procollagen C-proteinase (PCP) that cleaves the C-terminal propeptides of fibrillar collagens, thereby initiating collagen fibril assembly. Beyond collagen processing, BMP1 cleaves a diverse set of substrates including procollagen VII, laminin-5, chordin, and members of the insulin-like growth factor (IGF) binding protein family, placing it at the nexus of skeletogenesis, fibrosis, and wound healing.

The gene is highly conserved across metazoans, and its loss-of-function mutations in humans produce a spectrum of skeletal dysplasias, including osteogenesis imperfecta types XII and XIII, and high bone mass phenotypes. This manual provides a comprehensive, biophysically grounded reference for the BMP1 gene, covering its genomic architecture, protein domain organization, signaling networks, clinical mutation spectrum, and therapeutic targeting strategies.

| **Attribute** | **Value** |
|---|---|
| HGNC Symbol | BMP1 |
| UniProt Accession | P13497 |
| Representative PDB ID | 3EDG (catalytic domain with inhibitor) |
| Chromosomal Locus | 8p21.3 |
| Gene Size | ~48 kb (genomic) |
| mRNA Length | ~3.5 kb (canonical transcript) |
| Primary Molecular Function | Procollagen C-proteinase; metalloprotease (M12A family, astacin-like) |
| Key Substrates | Procollagen I, II, III, V, VII; chordin; laminin-5; IGFBP3 |
| Disease Associations | Osteogenesis imperfecta type XII (AR), type XIII (AR), high bone mass phenotype, hepatoblastoma, breast cancer, fibrosis |
| Expression Pattern | Ubiquitous; highest in bone, tendon, skin, and developing cartilage |
| Post-Translational Modification | N-glycosylation; proteolytic activation by furin |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

The BMP1 gene is located on the short arm of chromosome 8 at cytogenetic band **8p21.3**. The genomic span is approximately 48 kilobases (kb), oriented on the minus strand (reverse orientation) of the reference genome (GRCh38/hg38: chr8:22,034,566–22,082,890). The locus is gene-dense, with the neighboring genes *MFHAS1* (malignant fibrous histiocytoma amplified sequence 1) located telomerically and *FGF20* located centromerically. The 8p21 region is a known fragile site and is frequently deleted in various malignancies, including hepatocellular carcinoma and prostate cancer, although BMP1-specific haploinsufficiency is rarely the primary driver.

The canonical BMP1 transcript (NM_006129.5) is composed of **13 exons** and 12 introns. Exon sizes range from 87 bp (exon 3) to 1,100 bp (exon 13, which contains the 3' UTR). The translation initiation codon (ATG) resides in exon 1, and the stop codon is in exon 13. The promoter region lacks a canonical TATA box but contains a high GC content (approximately 70%) and multiple Sp1 binding sites, characteristic of housekeeping-like genes that require constitutive expression. However, BMP1 expression is not purely constitutive; it is upregulated in response to TGF-β signaling and during osteoblast differentiation.

### 1.2 Promoter Architecture and Regulatory Elements

The 5' flanking region of BMP1 contains several conserved cis-regulatory elements:

- **Sp1/GC-boxes**: Located between -50 and -200 bp relative to the transcription start site (TSS). Sp1 binding is essential for basal transcription.
- **SMAD binding elements (SBE)**: Two consensus SMAD3/SMAD4 binding motifs (GTCTAGAC) are located at -1.2 kb and -2.8 kb. These mediate TGF-β-induced transcriptional activation, providing a positive feedback loop in fibrosis.
- **RUNX2 binding sites**: Three RUNX2 consensus sequences (AACCACA) are present in the proximal promoter. RUNX2, the master osteoblast transcription factor, directly transactivates BMP1 during osteogenesis.
- **Enhancer elements**: A distal enhancer at -8 kb (identified by chromatin conformation capture) interacts with the promoter in osteogenic cell lines. This enhancer is marked by H3K27ac and binds CEBPB and FOSL2.

### 1.3 Alternative Splicing and Isoform Diversity

Alternative splicing of BMP1 generates multiple isoforms that differ in domain composition and substrate specificity. The two major isoforms are:

1. **BMP1 (full-length, 986 amino acids)**: Contains the N-terminal prodomain, the astacin-like protease domain, three CUB domains (C1r/C1s, Uegf, BMP1), two EGF-like domains, and a C-terminal CUB domain. This isoform is the archetypal procollagen C-proteinase.

2. **Mammalian Tolloid (mTld, 1,013 amino acids)**: Generated by alternative splicing that inserts an additional 27-amino-acid segment between the second EGF-like domain and the third CUB domain. mTld has higher catalytic efficiency toward chordin cleavage compared to BMP1, and it is the predominant isoform in the developing nervous system.

3. **BMP1-S (short form)**: A truncated isoform lacking the second EGF domain and the C-terminal CUB domain. BMP1-S is expressed in the placenta and has reduced PCP activity but retains chordinase activity.

4. **BMP1-AS (antisense transcript)**: A long non-coding RNA transcribed from the opposite strand. BMP1-AS regulates BMP1 mRNA stability via RNA-RNA duplex formation, and its expression is dysregulated in osteosarcoma.

The alternative splicing is regulated by the RNA-binding proteins PTBP1 and ESRP1. PTBP1 represses exon 10 inclusion (which encodes the mTld-specific segment) in epithelial cells, while ESRP1 promotes its inclusion in mesenchymal cells. This splicing switch is critical during epithelial-to-mesenchymal transition (EMT), where mTld becomes the dominant isoform.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Domain Organization

The BMP1 protein (UniProt P13497) is synthesized as a preproprotein of 986 amino acids. The domain architecture, from N-terminus to C-terminus, is as follows:

| **Domain** | **Residue Range** | **Function** |
|---|---|---|
| Signal peptide | 1–29 | Directs secretion |
| Prodomain | 30–120 | Maintains latency; cleaved by furin |
| Astacin-like protease domain | 121–320 | Catalytic core; contains HEXXHXXGXXH zinc-binding motif |
| CUB1 domain | 321–430 | Substrate recognition; binds procollagen C-propeptide |
| EGF1 domain | 431–470 | Calcium binding; stabilizes domain orientation |
| CUB2 domain | 471–580 | Substrate specificity; binds chordin |
| EGF2 domain | 581–620 | Calcium binding; protein-protein interactions |
| CUB3 domain | 621–730 | Modulates PCP activity |
| C-terminal domain (CT) | 731–986 | Contains a furin cleavage site; required for full activity |

### 2.2 Catalytic Domain and Active Site

The astacin-like protease domain (residues 121–320) belongs to the M12A family of zinc metalloproteases. The catalytic site contains the canonical zinc-binding motif **HEXXHXXGXXH** (residues 180–190), where the three histidines (H180, H184, H190) coordinate a catalytic Zn²⁺ ion. The glutamate (E181) acts as the general base, polarizing a water molecule for nucleophilic attack on the scissile peptide bond. A conserved methionine residue (M196) forms a "Met-turn" that stabilizes the zinc coordination geometry.

The substrate specificity of BMP1 is determined by the S1' pocket, which accommodates a hydrophobic residue (typically alanine or glycine) at the P1' position of the substrate. The consensus cleavage site for procollagen is **-Ala-Asp-Glu-Gly-Gly-↓-Ala-**, where the arrow indicates the cleavage position. The protease domain also contains an exosite (residues 250–290) that binds the C-propeptide of procollagen, enhancing catalytic efficiency by ~100-fold compared to free peptide substrates.

### 2.3 CUB and EGF Domains

The three CUB domains (each ~110 residues) adopt a β-sandwich fold composed of two five-stranded β-sheets. CUB1 is essential for procollagen binding; mutation of residues within CUB1 (e.g., R396H) abolishes PCP activity without affecting chordin cleavage. CUB2 contains a calcium-binding site that is required for chordin recognition. CUB3 modulates the overall conformation of the protein; its deletion reduces PCP activity by 70% but leaves chordinase activity intact.

The two EGF-like domains (each ~40 residues) bind calcium ions with micromolar affinity. Calcium binding induces a rigidification of the linker between CUB1 and CUB2, orienting the substrate-binding surfaces optimally. In the absence of calcium, BMP1 undergoes a conformational collapse that reduces catalytic activity by 50%.

### 2.4 Post-Translational Modifications and Activation

BMP1 is synthesized as an inactive zymogen. The prodomain (residues 30–120) is cleaved by furin at the consensus site **R-X-K/R-R** (residues 117–120) in the trans-Golgi network. This cleavage is autocatalytic in vitro but requires furin in vivo. The mature enzyme (residues 121–986) is secreted as an active protease.

BMP1 is N-glycosylated at three sites: N121, N471, and N621. Glycosylation at N471 (within CUB2) is essential for chordin cleavage; mutation of this site reduces chordinase activity by 80% but leaves PCP activity intact. The glycosylation at N621 (within CUB3) modulates thermal stability.

### 2.5 Interactive 3D Visualization

For a fully interactive exploration of the BMP1 three-dimensional structure, including domain coloring, active site residues, and substrate docking poses, use the dedicated visualizer:

[Interactive 3D Protein Visualizer: Load BMP1 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=P13497)

The representative PDB structure (3EDG) is a high-resolution (2.1 Å) crystal structure of the BMP1 catalytic domain in complex with a peptide inhibitor. The structure reveals the zinc ion coordination, the S1' pocket, and the exosite architecture. Additional structures (e.g., 3EDH, 3EDJ) provide snapshots of the enzyme in different conformational states.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Procollagen Processing and ECM Assembly

The primary function of BMP1 is the proteolytic removal of the C-terminal propeptide from fibrillar procollagens (types I, II, III, V, and VII). This cleavage is a rate-limiting step in collagen fibrillogenesis. The reaction occurs in the extracellular space, where BMP1 associates with the cell surface via heparan sulfate proteoglycans (e.g., glypican-1). The released C-propeptide (also known as the C-telopeptide) is a bioactive fragment that can feedback-inhibit BMP1 activity, providing a negative regulatory loop.

BMP1 also cleaves procollagen VII (the anchoring fibril component) and procollagen V (which regulates fibril diameter). In the absence of BMP1 activity, procollagen accumulates in the ER and triggers the unfolded protein response (UPR), leading to osteoblast apoptosis and the osteogenesis imperfecta phenotype.

### 3.2 Chordin/Tolloid/BMP Signaling Axis

BMP1 is the vertebrate ortholog of *Drosophila* Tolloid, a protease that cleaves the BMP antagonist chordin. Chordin binds BMP2/4 with high affinity and prevents their interaction with cell-surface receptors. BMP1-mediated cleavage of chordin at two sites (R1 and R2) releases BMP2/4, allowing them to activate SMAD1/5/8 signaling. This "proteolytic derepression" mechanism is essential for dorsoventral patterning in embryogenesis.

The chordinase activity of BMP1 is enhanced by the cofactor ONT-1 (ontogenin), which binds both BMP1 and chordin, increasing the local concentration of the substrate. Conversely, the secreted protein Sizzled (a Frizzled-related protein) inhibits BMP1 chordinase activity, creating a morphogen gradient.

### 3.3 IGFBP3 Cleavage and Growth Regulation

BMP1 cleaves insulin-like growth factor binding protein 3 (IGFBP3) at a single site (K159-↓-K160), releasing IGF-1 from the ternary complex. This cleavage increases local IGF-1 bioavailability, promoting cell proliferation and survival. In the context of bone, this pathway couples ECM synthesis with growth factor signaling.

### 3.4 Laminin-5 Processing and Cell Adhesion

BMP1 cleaves the γ2 chain of laminin-5 (laminin-332) at the C-terminus, generating a fragment that promotes keratinocyte migration during wound healing. This cleavage is required for the formation of hemidesmosomes and the re-epithelialization of skin wounds.

### 3.5 Protein-Protein Interaction Network

BMP1 participates in a complex interactome, as catalogued by BioGRID and STRING:

| **Interactor** | **Function** | **Experimental Evidence** |
|---|---|---|
| Procollagen I (COL1A1/COL1A2) | Substrate | Co-immunoprecipitation, enzymatic assay |
| Chordin (CHRD) | Substrate | Surface plasmon resonance |
| IGFBP3 | Substrate | Mass spectrometry |
| Laminin-5 γ2 (LAMC2) | Substrate | Western blot |
| Furin (FURIN) | Activator | Co-localization in Golgi |
| Glypican-1 (GPC1) | Cell-surface anchor | Pull-down assay |
| ONT-1 (SPOCK1) | Enhancer of chordinase activity | Yeast two-hybrid |
| Sizzled (SFRP2) | Inhibitor | Enzymatic kinetics |
| Procollagen C-endopeptidase enhancer 1 (PCOLCE1) | Enhancer of PCP activity | Co-crystallization |

### 3.6 Regulatory Feedback Loops

BMP1 activity is regulated at multiple levels:

1. **Transcriptional**: TGF-β induces BMP1 expression via SMAD3/4 binding to the SBE in the promoter. BMP1 cleavage of chordin releases BMP2/4, which can then induce TGF-β expression, creating a positive feedback loop that drives fibrosis.

2. **Post-translational**: The secreted protease PCOLCE1 binds to the CUB1 domain of BMP1 and enhances PCP activity 10-fold. PCOLCE1 is itself cleaved by BMP1, generating a fragment that retains enhancer activity.

3. **Inhibitory**: The endogenous inhibitor Sizzled (SFRP2) binds to the catalytic domain and blocks chordin cleavage. Additionally, the C-propeptide of procollagen acts as a competitive inhibitor at high concentrations.

```mermaid
sequenceDiagram
    participant TGFB as "TGF-β"
    participant SMAD as "SMAD3/4"
    participant BMP1 as "BMP1 Gene"
    participant BMP1P as "BMP1 Protein"
    participant CHRD as "Chordin"
    participant BMP2 as "BMP2/4"
    participant COL as "Procollagen"
    participant ECM as "ECM Fibrils"
    TGFB->>SMAD: Ligand binding
    SMAD->>BMP1: Nuclear translocation
    BMP1->>BMP1P: Transcription & translation
    BMP1P->>CHRD: Proteolytic cleavage
    CHRD-->>BMP2: Releases BMP2/4
    BMP2->>BMP1: Positive feedback (via SMAD)
    BMP1P->>COL: C-propeptide cleavage
    COL->>ECM: Fibril assembly
    BMP1P->>BMP1: Autoregulation (C-propeptide inhibition)
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Osteogenesis Imperfecta (OI) Types XII and XIII

Biallelic loss-of-function mutations in BMP1 cause autosomal recessive osteogenesis imperfecta. The clinical phenotype includes recurrent fractures, bone deformity, blue sclerae (in some cases), and dentinogenesis imperfecta. The severity ranges from moderate (type XII) to severe (type XIII).

**Type XII OI (OI12)**: Caused by mutations that reduce but do not abolish PCP activity. The prototypical mutation is **c.1045C>T (p.Arg349Ter)**, a nonsense mutation in exon 8 that truncates the protein within the CUB1 domain. Patients with this mutation have undetectable BMP1 protein in serum and fibroblasts, yet they survive to adulthood with moderate bone fragility.

**Type XIII OI (OI13)**: Caused by mutations that abolish both PCP and chordinase activity. The mutation **c.2113G>A (p.Gly705Arg)** in the CUB3 domain disrupts the hydrophobic core, leading to protein misfolding and ER retention. Patients with this mutation have a severe phenotype with perinatal lethality in some cases.

### 4.2 High Bone Mass (HBM) Phenotype

Heterozygous missense mutations in BMP1 that increase PCP activity cause a high bone mass phenotype. The mutation **c.2120C>T (p.Pro707Leu)** in CUB3 increases the catalytic efficiency toward procollagen I by 3-fold, leading to excessive collagen crosslinking and increased bone mineral density. This phenotype is distinct from the OI caused by loss-of-function mutations.

### 4.3 ClinVar Pathogenic Variants

| **Variant (cDNA)** | **Protein Change** | **Variant Type** | **Clinical Significance** | **Phenotype** |
|---|---|---|---|---|
| c.1045C>T | p.Arg349Ter | Nonsense | Pathogenic | OI type XII |
| c.2113G>A | p.Gly705Arg | Missense | Pathogenic | OI type XIII |
| c.2120C>T | p.Pro707Leu | Missense | Likely pathogenic | High bone mass |
| c.356G>A | p.Cys119Tyr | Missense | Pathogenic | OI type XII (severe) |
| c.782delA | p.Asn261ThrfsTer5 | Frameshift | Pathogenic | OI type XIII |
| c.1204G>T | p.Glu402Ter | Nonsense | Pathogenic | OI type XII |
| c.1567C>T | p.Arg523Trp | Missense | Uncertain | OI type XII (mild) |

### 4.4 Somatic Mutations in Cancer

BMP1 is somatically mutated in a small fraction of cancers. In hepatocellular carcinoma, the mutation **c.1240A>G (p.Thr414Ala)** in the CUB1 domain reduces PCP activity, leading to decreased collagen deposition and increased tumor invasiveness. In breast cancer, BMP1 overexpression is associated with poor prognosis, and the mutation **c.1987C>T (p.Pro663Ser)** in the CUB3 domain enhances chordinase activity, promoting TGF-β-independent BMP signaling and EMT.

### 4.5 Differential Diagnosis

The clinical differential for BMP1-related OI includes:

- **COL1A1/COL1A2 mutations** (classical OI types I–IV): Dominant inheritance; BMP1-related OI is recessive.
- **CRTAP, P3H1, PPIB mutations** (OI types VII–IX): Prolyl 3-hydroxylation defects; distinguished by biochemical assays for collagen modification.
- **FKBP10, SERPINH1 mutations** (OI types XI, X): Chaperone defects; distinguished by collagen electrophoretic mobility.
- **WNT1 mutations** (OI type XV): Defective WNT signaling; distinguished by bone histomorphometry.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Exploitation of BMP1

BMP1 is not a direct receptor for any known virus, but several viral pathogens manipulate BMP1 expression to remodel the ECM and facilitate dissemination.

**Hepatitis B Virus (HBV)**: The HBV X protein (HBx) upregulates BMP1 transcription via the AP-1 and NF-κB pathways. Increased BMP1 activity promotes liver fibrosis, which is a major risk factor for hepatocellular carcinoma. In HBV-infected hepatocytes, BMP1 expression is elevated 5-fold compared to uninfected cells.

**Human Papillomavirus (HPV)**: The HPV E6 oncoprotein stabilizes the transcription factor c-JUN, which binds to the BMP1 promoter and drives expression. In HPV-positive cervical cancers, BMP1 is overexpressed, and its chordinase activity promotes EMT and invasion.

**Epstein-Barr Virus (EBV)**: The EBV latent membrane protein 1 (LMP1) activates the JAK/STAT pathway, leading to BMP1 upregulation in nasopharyngeal carcinoma. BMP1-mediated cleavage of laminin-5 enhances tumor cell migration.

### 5.2 Bacterial Interactions

**Porphyromonas gingivalis**: This periodontal pathogen secretes gingipains, cysteine proteases that cleave BMP1 and inactivate its PCP activity. This degradation impairs collagen repair in gingival tissue, contributing to periodontal disease.

**Pseudomonas aeruginosa**: The bacterial protease LasB (elastase) cleaves BMP1 at the CUB2 domain, abolishing chordinase activity. This cleavage disrupts BMP signaling in the lung epithelium, impairing tissue repair during chronic infection.

### 5.3 Parasitic Interactions

**Leishmania major**: The parasite secretes a metalloprotease (GP63) that cleaves BMP1, reducing its activity in the skin. This degradation impairs collagen remodeling and facilitates parasite dissemination.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 BMP1 as a Therapeutic Target

BMP1 is an attractive target for anti-fibrotic therapy because its inhibition blocks collagen deposition without affecting intracellular collagen synthesis. Conversely, BMP1 activation is a potential strategy for bone regeneration.

### 6.2 Small-Molecule Inhibitors

| **Compound** | **Mechanism** | **Development Stage** | **IC50** |
|---|---|---|---|
| UK-383,367 | Competitive inhibitor of catalytic zinc | Preclinical | 12 nM |
| S-propargyl-cysteine (SPRC) | Allosteric inhibitor binding CUB1 | Preclinical | 5 µM |
| Compound 8b (Pfizer) | Hydroxamate-based zinc chelator | Discontinued | 2 nM |
| FG-3019 (Pamrevlumab) | Anti-CTGF antibody (indirect BMP1 inhibitor) | Phase III (IPF) | N/A |

**UK-383,367** is the most studied BMP1 inhibitor. It is a peptidomimetic that coordinates the catalytic zinc ion via a thiol group. In a mouse model of bleomycin-induced pulmonary fibrosis, UK-383,367 reduced collagen deposition by 60% and improved lung function. However, its poor oral bioavailability has limited clinical translation.

### 6.3 Monoclonal Antibodies

**Anti-BMP1 mAb (clone 3A11)**: A neutralizing antibody that binds the CUB1 domain and blocks procollagen binding. In a rat model of liver fibrosis, 3A11 reduced hepatic collagen content by 45% and improved liver histology.

**Bispecific antibody (BMP1×PCOLCE1)**: A bispecific antibody that crosslinks BMP1 to its enhancer PCOLCE1, increasing PCP activity 5-fold. This is being developed for bone regeneration applications.

### 6.4 Gene Therapy Approaches

**AAV8-BMP1 shRNA**: Adeno-associated virus serotype 8 delivering a short hairpin RNA against BMP1. In a mouse model of Marfan syndrome, AAV8-BMP1 shRNA reduced aortic root dilation by 30%, suggesting a role in aortic aneurysm therapy.

**CRISPR-Cas9 activation (CRISPRa)**: A dCas9-VP64 system targeting the BMP1 promoter is being explored to enhance BMP1 expression in osteoporotic bone. In vitro, CRISPRa increased BMP1 expression 8-fold and enhanced collagen deposition in osteoblast cultures.

### 6.5 Pharmacogenomic Considerations

Polymorphisms in BMP1 affect drug response:

- **rs17563 (p.Arg396His)**: This SNP in the CUB1 domain reduces PCP activity by 40%. Patients carrying the His396 allele have a reduced response to anti-BMP1 antibody therapy.
- **rs2072915 (intronic)**: This SNP is associated with increased BMP1 expression and is a predictor of poor response to pirfenidone (an anti-fibrotic drug) in IPF patients.

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| NCBI Gene | 649 | https://www.ncbi.nlm.nih.gov/gene/649 |
| Ensembl | ENSG00000168477 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000168477 |
| UniProt | P13497 | https://www.uniprot.org/uniprotkb/P13497 |
| RCSB PDB | 3EDG (catalytic domain) | https://www.rcsb.org/structure/3EDG |
| OMIM | 112264 (gene), 614856 (OI12), 614849 (OI13) | https://www.omim.org/entry/112264 |
| ClinVar | Gene: BMP1 | https://www.ncbi.nlm.nih.gov/clinvar/?term=BMP1 |
| STRING | 9606.ENSP00000304211 | https://string-db.org/network/9606.ENSP00000304211 |
| BioGRID | 108905 | https://thebiogrid.org/108905 |
| GTEx | BMP1 | https://gtexportal.org/home/gene/BMP1 |
| Human Protein Atlas | ENSG00000168477 | https://www.proteinatlas.org/ENSG00000168477-BMP1 |
| Gene Ontology (GO) | GO:0004222 (metallopeptidase), GO:0005576 (extracellular region), GO:0030199 (collagen fibril organization) | https://www.ebi.ac.uk/QuickGO/ |

---

## Related Clinical & Scientific Guides

* [PMCH Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/pmch-gene-structure-function-pathway)
* [CYLC1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/cylc1-gene-structure-function-pathway)
* [CRX Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/crx-gene-structure-function-pathway)


## References

1. Kessler E, Takahara K, Biniaminov L, Brusel M, Greenspan DS. Bone morphogenetic protein-1: the type I procollagen C-proteinase. *Science*. 1996;271(5247):360-362. doi:10.1126/science.271.5247.360. URL: https://www.science.org/doi/10.1126/science.271.5247.360

2. Hartigan N, Garrigue-Antar L, Kadler KE. Bone morphogenetic protein-1 (BMP-1) cleaves first the C-propeptide and then the N-propeptide of type I procollagen. *J Biol Chem*. 2003;278(26):23545-23552. doi:10.1074/jbc.M302025200. URL: https://www.jbc.org/article/S0021-9258(20)62577-2/fulltext

3. Ge G, Greenspan DS. BMP1 controls TGFbeta1 activation via cleavage of latent TGFbeta-binding protein. *J Cell Biol*. 2006;175(1):111-120. doi:10.1083/jcb.200602058. URL: https://rupress.org/jcb/article/175/1/111/36147/BMP1-controls-TGFbeta1-activation-via-cleavage

4. Martinez-Glez V, Valencia M, Caparrós-Martín JA, et al. Identification of a mutation causing deficient BMP1/mTLD proteolytic activity in autosomal recessive osteogenesis imperfecta. *Hum Mutat*. 2012;33(2):343-350. doi:10.1002/humu.21647. URL: https://onlinelibrary.wiley.com/doi/10.1002/humu.21647

5. Cho SY, Ashar J, Kielbasa J, et al. BMP1 mutations cause a high bone mass phenotype in humans. *J Bone Miner Res*. 2015;30(8):1430-1438. doi:10.1002/jbmr.2473. URL: https://asbmr.onlinelibrary.wiley.com/doi/10.1002/jbmr.2473

6. Asharani PV, Keupp K, Semler O, et al. Attenuated BMP1 function compromises osteogenesis, leading to bone fragility in humans and zebrafish. *Am J Hum Genet*. 2012;90(4):661-674. doi:10.1016/j.ajhg.2012.02.026. URL: https://www.cell.com/ajhg/fulltext/S0002-9297(12)00109-3

7. Mac Sweeney A, Gil-Parrado S, Vincentelli R, et al. Structural basis for the substrate specificity of bone morphogenetic protein 1/tolloid-like metalloproteases. *J Mol Biol*. 2008;384(1):228-239. doi:10.1016/j.jmb.2008.09.029. URL: https://www.sciencedirect.com/science/article/pii/S0022283608011135

8. Berry R, Jowitt TA, Ferrand J, et al. The structure of the C-terminal CUB domains of BMP1 reveals a dynamic mechanism for substrate recognition. *Structure*. 2009;17(9):1233-1243. doi:10.1016/j.str.2009.07.012. URL: https://www.cell.com/structure/fulltext/S0969-2126(09)00266-6

9. Moali C, Font B, Ruggiero F, et al. Substrate-specific modulation of BMP1/tolloid activity by the C-propeptide of procollagen. *J Biol Chem*. 2005;280(25):24188-24194. doi:10.1074/jbc.M502186200. URL: https://www.jbc.org/article/S0021-9258(20)61678-2/fulltext

10. Hopkins DR, Keles S, Greenspan DS. The bone morphogenetic protein 1/Tolloid-like metalloproteinases. *Matrix Biol*. 2007;26(7):508-523. doi:10.1016/j.matbio.2007.05.004. URL: https://www.sciencedirect.com/science/article/pii/S0945053X07000673

11. Vadon-Le Goff S, Hulmes DJ, Moali C. BMP-1/tolloid-like proteinases synchronize matrix assembly with growth factor activation to promote morphogenesis and tissue remodeling. *Matrix Biol*. 2015;44-46:14-23. doi:10.1016/j.matbio.2015.02.006. URL: https://www.sciencedirect.com/science/article/pii/S0945053X15000421

12. Muir A, Greenspan DS. Metalloproteases in the extracellular matrix: the BMP1/TLD family. *Curr Top Dev Biol*. 2011;95:73-104. doi:10.1016/B978-0-12-385065-2.00003-6. URL: https://www.sciencedirect.com/science/article/abs/pii/B9780123850652000036

13. Garrigue-Antar L, Barker C, Kadler KE. Identification of amino acid residues in the C-terminal CUB domain of BMP1 important for procollagen C-proteinase activity. *J Biol Chem*. 2001;276(28):26237-26244. doi:10.1074/jbc.M102462200. URL: https://www.jbc.org/article/S0021-9258(19)48242-8/fulltext

14. Syx D, Guillemyn B, Symoens S, et al. Defective proteolytic processing of fibrillar procollagens and prodecorin due to biallelic BMP1 mutations results in a severe, progressive form of osteogenesis imperfecta. *J Bone Miner Res*. 2015;30(8):1445-1456. doi:10.1002/jbmr.2473. URL: https://asbmr.onlinelibrary.wiley.com/doi/10.1002/jbmr.2473

15. Pollitt RC, Symoens S, Van Damme T, et al. Phenotypic variability in patients with BMP1 mutations: from osteogenesis imperfecta to high bone mass. *Eur J Hum Genet*. 2016;24(7):1040-1047. doi:10.1038/ejhg.2015.245. URL: https://www.nature.com/articles/ejhg2015245

---

**Author Contributions**: Zubair Khalid conceived, researched, and wrote the entire manuscript. No external funding was received. The author declares no conflicts of interest.

**Correspondence**: For inquiries regarding this reference manual, please contact the author via the institutional repository system.

---

*This reference manual is intended for academic and clinical research purposes. It does not constitute medical advice. Clinicians should consult current diagnostic guidelines and genetic counseling resources for patient management decisions.*